Tejus V
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Tejus V has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Arup Kumar Misra
Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India
1 shared publication - Gaurav Rangari
Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri andhra Pradesh, India
1 shared publication - Golla Varshitha
Department of Internal Medicine International School of Medicine (ISM) Bishkek Kyrgyzstan
1 shared publication - Lakshmi Venkata Simhachalam Kutikuppala
Department of General Surgery Dr YSR University of Health Sciences Vijayawada Andhra Pradesh India
1 shared publication - Madhavrao Chavan
Department of Pharamacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India
1 shared publication - Sai Ram Innamuri
Department of Pharamacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India
1 shared publication
Latest Publications
- Open Access
- 19 December 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 926-929
Bromocriptine: does this drug of Parkinson’s disease have a role in managing cardiovascular diseases?
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality worldwide. Bromocriptine is a partial antagonist for D1 dopamine receptors while also serving as a selective agonist on D2 dopamine receptors as a dopamine receptor agonist. Apart from prolactin inhibiting action, bromocriptine has some beneficial effects on the blood pressure, plasma norepinephrine levels and vascular resistance. Dopamine D2 receptor activation of bromocriptine is associated with the antihypertensive effect, which lowers blood pressure via inhibiting sympathetic nerve activity and Na/K ATPase activity. Plasma levels of the pro-inflammatory cytokines such as interleukin (IL)-1B and IL-18, chemokine CCL2/ MCP-1/, and the pro-inflammatory hormone prolactin, all of which are elevated and linked to accelerated cardiometabolic illness, were decreased because of bromocriptine therapy. The most common side effects of Bromocriptine use are dizziness, nausea, headache, vomiting and hypotension. Bromocriptine is mainly contraindicated in patients with syncope with hypotension, psychosis, and type I diabetes mellitus. The authors suggest that developing therapies directed to increase D2 receptor expression and function by drugs like Bromocriptine can provide practical and novelistic approaches to prevent and manage myocardial and renal injury in the cardiovascular disease patients.
- 19 December 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 926-929
Open AccessBromocriptine: does this drug of Parkinson’s disease have a role in managing cardiovascular diseases?
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality worldwide. Bromocriptine is a partial antagonist for D1 dopamine receptors while also serving as a selective agonist on D2 dopamine receptors as a dopamine receptor agonist. Apart from prolactin inhibiting action, bromocriptine has some beneficial effects on the blood pressure, plasma norepinephrine levels and vascular resistance. Dopamine D2 receptor activation of bromocriptine is associated with the antihypertensive effect, which lowers blood pressure via inhibiting sympathetic nerve activity and Na/K ATPase activity. Plasma levels of the pro-inflammatory cytokines such as interleukin (IL)-1B and IL-18, chemokine CCL2/ MCP-1/, and the pro-inflammatory hormone prolactin, all of which are elevated and linked to accelerated cardiometabolic illness, were decreased because of bromocriptine therapy. The most common side effects of Bromocriptine use are dizziness, nausea, headache, vomiting and hypotension. Bromocriptine is mainly contraindicated in patients with syncope with hypotension, psychosis, and type I diabetes mellitus. The authors suggest that developing therapies directed to increase D2 receptor expression and function by drugs like Bromocriptine can provide practical and novelistic approaches to prevent and manage myocardial and renal injury in the cardiovascular disease patients.